SI3241843T1 - Optimizacija topnosti imunoveziv - Google Patents

Optimizacija topnosti imunoveziv

Info

Publication number: SI3241843T1
Authority: SI; Slovenia
Prior art keywords: immunobinders; solubility optimization; solubility; optimization
Prior art date: 2008-06-25

Application number

SI200932137T

Other languages

English (en)

Inventor

Leonardo Borras

David Urech

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-25

Filing date

2009-06-25

Publication date

2021-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228195&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3241843(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-25 Application filed by Novartis Ag filed Critical Novartis Ag

2021-11-30 Publication of SI3241843T1 publication Critical patent/SI3241843T1/sl

Links

238000005457 optimization Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

SI200932137T 2008-06-25 2009-06-25 Optimizacija topnosti imunoveziv SI3241843T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7569208P	2008-06-25	2008-06-25
EP17161990.1A EP3241843B1 (en)	2008-06-25	2009-06-25	Solubility optimization of immunobinders

Publications (1)

Publication Number	Publication Date
SI3241843T1 true SI3241843T1 (sl)	2021-11-30

Family

ID=41228195

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200931674A SI2307455T1 (sl)	2008-06-25	2009-06-25	Optimizacija topnosti imunoveziv
SI200932137T SI3241843T1 (sl)	2008-06-25	2009-06-25	Optimizacija topnosti imunoveziv

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI200931674A SI2307455T1 (sl)	2008-06-25	2009-06-25	Optimizacija topnosti imunoveziv

Country Status (21)

Country	Link
US (3)	US9556265B2 (sl)
EP (2)	EP3241843B1 (sl)
JP (3)	JP5745720B2 (sl)
KR (2)	KR101650165B1 (sl)
CN (2)	CN105418763A (sl)
AU (1)	AU2009264566B2 (sl)
BR (1)	BRPI0914666A2 (sl)
CA (1)	CA2728829C (sl)
CY (2)	CY1119626T1 (sl)
DK (2)	DK3241843T3 (sl)
ES (2)	ES2629345T3 (sl)
HR (2)	HRP20171250T1 (sl)
HU (2)	HUE034827T2 (sl)
LT (2)	LT3241843T (sl)
MX (2)	MX2011000074A (sl)
PL (2)	PL2307455T3 (sl)
PT (2)	PT2307455T (sl)
RU (3)	RU2514658C2 (sl)
SI (2)	SI2307455T1 (sl)
WO (1)	WO2009155725A1 (sl)
ZA (1)	ZA201008595B (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2009264567B2 (en)	2008-06-25	2014-06-12	Novartis Ag	Humanization of rabbit antibodies using a universal antibody framework
KR101650165B1 (ko)	2008-06-25	2016-08-22	에스바테크 - 어 노바티스 컴파니 엘엘씨	면역결합제의 용해도 최적화
WO2009155723A2 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CN102143976B (zh)	2008-06-25	2015-11-25	艾斯巴技术-诺华有限责任公司	抑制vegf的稳定和可溶的抗体
US8399625B1 (en)	2009-06-25	2013-03-19	ESBATech, an Alcon Biomedical Research Unit, LLC	Acceptor framework for CDR grafting
US8796425B2 (en)	2009-12-23	2014-08-05	Esbatech, An Alcon Biomedical Research Unit Llc	Method for decreasing immunogenicity
AU2014262201B2 (en) *	2009-12-23	2016-09-15	Novartis Ag	Method for decreasing immunogenicity
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
EP2670778A1 (en) *	2011-02-02	2013-12-11	Glaxo Group Limited	Novel antigen binding proteins
KR102345999B1 (ko)	2012-11-05	2021-12-30	델레넥스 쎄라퓨틱스 아게	Il-1 베타 결합성분
EP4001307A1 (en)	2012-12-17	2022-05-25	Cell Medica Inc.	Antibodies against il-1 beta
WO2014124677A1 (en) *	2013-02-15	2014-08-21	Esbatech - A Novartis Company Llc	Acceptor framework for cdr grafting
EP2958939A1 (en) *	2013-02-20	2015-12-30	ESBATech - a Novartis Company LLC	Acceptor framework for cdr grafting
KR20180021234A (ko)	2013-08-12	2018-02-28	제넨테크, 인크.	보체-연관 상태의 치료를 위한 조성물 및 방법
EP3042205B1 (en) *	2013-09-06	2019-12-25	F. Hoffmann-La Roche AG	Method for improving antibody stability
WO2015168468A1 (en)	2014-05-01	2015-11-05	Genentech, Inc.	Anti-factor d antibody variants and uses thereof
EP3159346B1 (en) *	2015-10-21	2018-07-04	Trinseo Europe GmbH	Aminosilane-functionalized dienes for use in functionalization of elastomeric polymers
US11434294B2 (en)	2016-02-25	2022-09-06	Cell Medica, Inc.	Binding members to PD-L1
TW202246319A (zh)	2021-02-12	2022-12-01	德商百靈佳殷格翰國際股份有限公司	補體c3抗原結合蛋白
US20220340894A1 (en)	2021-03-09	2022-10-27	Cdr-Life Ag	Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
KR20230169944A (ko)	2021-03-09	2023-12-18	씨디알-라이프 아게	Mage-a4 펩티드-mhc 항원 결합 단백질
CA3240046A1 (en)	2021-12-14	2023-06-22	Cdr-Life Ag	Dual mhc-targeting t cell engager
US20240091262A1 (en)	2022-09-14	2024-03-21	Cdr-Life Ag	Mage-a4 peptide dual t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824307A (en)	1991-12-23	1998-10-20	Medimmune, Inc.	Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
NZ258392A (en)	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US6740734B1 (en)	1994-01-14	2004-05-25	Biovitrum Ab	Bacterial receptor structures
HU228630B1 (en)	1996-02-09	2013-04-29	Abbott Biotech Ltd	Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
WO1998002462A1 (en) *	1996-07-16	1998-01-22	Morphosys Gesellschaft Für Proteinoptimierung Mbh	Immunoglobulin superfamily domains and fragments with increased solubility
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US6673901B2 (en)	1997-06-12	2004-01-06	Research Corporation Technologies, Inc.	Artificial antibody polypeptides
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
EA004107B1 (ru)	1998-08-11	2003-12-25	Айдек Фармацевтикалс Корпорэйшн	Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6602977B1 (en)	1999-04-19	2003-08-05	Biovitrum Ab	Receptor structures
SE9901379D0 (sv)	1999-04-19	1999-04-19	Pharmacia & Upjohn Ab	Receptor structures
EP2392596A3 (en)	1999-12-28	2013-11-27	ESBATech, an Alcon Biomedical Research Unit LLC	Intrabodies with defined framework that is stable in a reducing environment and applications thereof
JP2003523771A (ja)	2000-02-25	2003-08-12	ザガバメントオブザユナイテッドステイツ，アズレプレゼンテッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	改善された細胞傷害性および収率を有する抗ＥＧＦＲｖＩＩＩｓｃＦｖ、それに基づく免疫毒素、ならびにその使用方法
WO2002020565A2 (en)	2000-09-08	2002-03-14	Universität Zürich	Collections of repeat proteins comprising repeat modules
US20030157561A1 (en)	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
US20030082630A1 (en)	2001-04-26	2003-05-01	Maxygen, Inc.	Combinatorial libraries of monomer domains
US6905608B2 (en)	2002-01-22	2005-06-14	Exergy Technologies Corporation	Advanced electrodeionization for fluid recycling
WO2003097697A2 (en)	2002-05-22	2003-11-27	Esbatech Ag	Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CA2526085A1 (en) *	2003-05-30	2005-01-06	Genentech, Inc.	Treatment with anti-vegf antibodies
AU2003264100A1 (en)	2003-08-25	2005-03-10	Pieris Proteolab Ag	Muteins of a bilin-binding protein with affinity for a given target
EP3225633B1 (en)	2004-05-21	2020-03-25	The UAB Research Foundation	Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
DK2390267T3 (da)	2005-06-07	2013-08-26	Esbatech A Novartis Co Llc	Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
CN101505794B (zh)	2006-07-10	2013-09-04	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	穿过上皮和/或内皮层的scFV抗体
EP2118138A1 (en)	2007-03-12	2009-11-18	Esbatech AG	Sequence based engineering and optimization of single chain antibodies
WO2009000098A2 (en)	2007-06-25	2008-12-31	Esbatech Ag	Sequence based engineering and optimization of single chain antibodies
CN102838673B (zh)	2007-06-25	2016-05-11	艾斯巴技术-诺华有限责任公司	修饰抗体的方法和具有改善的功能性质的修饰抗体
KR101650165B1 (ko)	2008-06-25	2016-08-22	에스바테크 - 어 노바티스 컴파니 엘엘씨	면역결합제의 용해도 최적화

2009
- 2009-06-25 KR KR1020117001959A patent/KR101650165B1/ko active IP Right Grant
- 2009-06-25 LT LTEP17161990.1T patent/LT3241843T/lt unknown
- 2009-06-25 US US13/000,460 patent/US9556265B2/en active Active
- 2009-06-25 CN CN201511018105.0A patent/CN105418763A/zh active Pending
- 2009-06-25 PL PL09768694T patent/PL2307455T3/pl unknown
- 2009-06-25 PT PT97686943T patent/PT2307455T/pt unknown
- 2009-06-25 RU RU2011102548/10A patent/RU2514658C2/ru active
- 2009-06-25 ES ES09768694.3T patent/ES2629345T3/es active Active
- 2009-06-25 LT LTEP09768694.3T patent/LT2307455T/lt unknown
- 2009-06-25 MX MX2011000074A patent/MX2011000074A/es active IP Right Grant
- 2009-06-25 EP EP17161990.1A patent/EP3241843B1/en active Active
- 2009-06-25 CN CN200980123815.6A patent/CN102076715B/zh active Active
- 2009-06-25 HU HUE09768694A patent/HUE034827T2/en unknown
- 2009-06-25 SI SI200931674A patent/SI2307455T1/sl unknown
- 2009-06-25 HU HUE17161990A patent/HUE056090T2/hu unknown
- 2009-06-25 ES ES17161990T patent/ES2884117T3/es active Active
- 2009-06-25 DK DK17161990.1T patent/DK3241843T3/da active
- 2009-06-25 EP EP09768694.3A patent/EP2307455B1/en not_active Revoked
- 2009-06-25 MX MX2013011865A patent/MX346024B/es unknown
- 2009-06-25 JP JP2011515050A patent/JP5745720B2/ja active Active
- 2009-06-25 WO PCT/CH2009/000221 patent/WO2009155725A1/en active Application Filing
- 2009-06-25 BR BRPI0914666A patent/BRPI0914666A2/pt not_active Application Discontinuation
- 2009-06-25 KR KR1020167017202A patent/KR101790567B1/ko active IP Right Grant
- 2009-06-25 PL PL17161990T patent/PL3241843T3/pl unknown
- 2009-06-25 SI SI200932137T patent/SI3241843T1/sl unknown
- 2009-06-25 PT PT171619901T patent/PT3241843T/pt unknown
- 2009-06-25 CA CA2728829A patent/CA2728829C/en active Active
- 2009-06-25 DK DK09768694.3T patent/DK2307455T3/en active
- 2009-06-25 AU AU2009264566A patent/AU2009264566B2/en active Active
2010
- 2010-11-30 ZA ZA2010/08595A patent/ZA201008595B/en unknown
2014
- 2014-02-10 RU RU2014104577A patent/RU2653441C2/ru active
- 2014-03-18 JP JP2014054856A patent/JP2014111667A/ja active Pending
2016
- 2016-04-06 JP JP2016076318A patent/JP2016128517A/ja active Pending
- 2016-12-14 US US15/378,649 patent/US10221237B2/en active Active
2017
- 2017-06-22 CY CY20171100670T patent/CY1119626T1/el unknown
- 2017-08-16 HR HRP20171250TT patent/HRP20171250T1/hr unknown
2018
- 2018-04-05 RU RU2018112257A patent/RU2018112257A/ru not_active Application Discontinuation
2019
- 2019-02-05 US US16/267,460 patent/US11046757B2/en active Active
2021
- 2021-08-25 HR HRP20211356TT patent/HRP20211356T1/hr unknown
- 2021-09-22 CY CY20211100832T patent/CY1124644T1/el unknown

Also Published As

Publication number	Publication date
JP5745720B2 (ja)	2015-07-08
JP2014111667A (ja)	2014-06-19
US9556265B2 (en)	2017-01-31
EP2307455A1 (en)	2011-04-13
EP2307455B1 (en)	2017-03-22
HRP20211356T1 (hr)	2021-11-26
CN102076715B (zh)	2018-06-19
AU2009264566A1 (en)	2009-12-30
RU2514658C2 (ru)	2014-04-27
KR101790567B1 (ko)	2017-10-26
AU2009264566B2 (en)	2014-05-08
CY1119626T1 (el)	2018-04-04
JP2011525496A (ja)	2011-09-22
MX2011000074A (es)	2011-02-24
HRP20171250T1 (hr)	2017-10-20
ES2884117T3 (es)	2021-12-10
MX346024B (es)	2017-03-02
DK2307455T3 (en)	2017-07-10
EP3241843B1 (en)	2021-07-28
PL3241843T3 (pl)	2021-12-27
HUE034827T2 (en)	2018-03-28
RU2011102548A (ru)	2012-07-27
LT2307455T (lt)	2017-06-26
RU2653441C2 (ru)	2018-05-08
HUE056090T2 (hu)	2022-01-28
KR20110022714A (ko)	2011-03-07
US20190169284A1 (en)	2019-06-06
CN102076715A (zh)	2011-05-25
CN105418763A (zh)	2016-03-23
US11046757B2 (en)	2021-06-29
RU2014104577A (ru)	2015-08-20
PT2307455T (pt)	2017-07-03
CA2728829A1 (en)	2009-12-30
CA2728829C (en)	2018-01-02
WO2009155725A1 (en)	2009-12-30
SI2307455T1 (sl)	2017-07-31
JP2016128517A (ja)	2016-07-14
PT3241843T (pt)	2021-09-10
BRPI0914666A2 (pt)	2015-10-20
PL2307455T3 (pl)	2017-09-29
ES2629345T3 (es)	2017-08-08
ZA201008595B (en)	2012-02-29
KR20160083129A (ko)	2016-07-11
US20110268728A1 (en)	2011-11-03
LT3241843T (lt)	2021-09-27
RU2018112257A (ru)	2019-10-09
CY1124644T1 (el)	2022-07-22
KR101650165B1 (ko)	2016-08-22
EP3241843A1 (en)	2017-11-08
US10221237B2 (en)	2019-03-05
US20170096482A1 (en)	2017-04-06
DK3241843T3 (da)	2021-09-06

Publication	Publication Date	Title
ZA201008595B (en)	2012-02-29	Solubility optimization of immunobinders
HK1173142A1 (en)	2013-05-10	N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5-
HK1172893A1 (en)	2013-05-03	5-fluoropyrimidinone derivatives 5-
IL219087A0 (en)	2012-06-28	Benzimidazole-imidazole derivatives
IL216007A0 (en)	2012-01-31	Isoxazole-pyridine derivatives
IL215109A0 (en)	2011-12-29	Isoxazole-pyridazine derivatives
IL214941A0 (en)	2011-11-30	Isoxazole-pyrazole derivatives
IL213927A0 (en)	2011-07-31	Deoxyactagardine derivatives
HK1172894A1 (en)	2013-05-03	N1-acyl-5-fluoropyrimidinone derivatives n1--5-
HK1169623A1 (en)	2013-02-01	Pyrazinooxazepine derivatives
IL218500A0 (en)	2012-07-31	Apogossypolone derivatives as anticaner agents
EP2512482A4 (en)	2013-05-22	DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
HK1173134A1 (en)	2013-05-10	Substituted halophenoxybenzamide derivatives
IL213262A0 (en)	2011-07-31	Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en)	2009-08-26	Indopyl-pyridone derivatives
GB0821710D0 (en)	2008-12-31	Derivatives of dihydroindolone
PL386302A1 (pl)	2010-04-26	Nowa pochodna izotiazolopirydyny